The role of thromboxane A 2 (TxA 2 ) in smokingassociated lung cancer is poorly understood. This study was conducted to study the role of TxA 2 in smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-promoted cell survival and growth in human lung cancer cells. We found that NNK increased TxA 2 synthase (TxAS) expression and thromboxane B 2 (TxB 2 ) generation in cultured lung cancer cells, the result of which was supported by the increased level of TxAS in lung cancer tissues of smokers. Both TxAS-specific inhibitor furegrelate and TxA 2 receptor antagonist SQ29548 completely blocked NNK-mediated cell survival and growth via inducting apoptosis. TxA 2 receptor agonist U46619 reconstituted a near-full survival and growth response to NNK when TxAS was inhibited, affirming the role of TxA 2 receptor in NNK-mediated cell survival and growth. Suppression of cyclic adenosine monophosphate response element binding protein (CREB) activity by its small interference RNA blocked the effect of NNK. Phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) also had a positive role. Altogether, our results have revealed that NNK stimulates TxA 2 synthesis and activates its receptor in lung cancer cells. The increased TxA 2 may then activate CREB through PI3K/Akt and extracellular ERK pathways, thereby contributing to the NNK-promoted survival and growth of lung cancer cells.
Introduction
Cigarette smoking represents the leading risk factor for all lung cancer types. Generally, about 85-90% of lung cancer cases are attributable to cigarette smoking (Hecht, 2002) . In addition, there is an approximate 20-fold increase in the risk of developing lung cancer for a lifetime smoker when compared with a lifetime nonsmoker (Parsons et al., 2010) . 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a nicotine-nitrosated derivative, is the major carcinogenic component in cigarette smoke. Since the polycyclic aromatic hydrocarbon of tobacco smoke was reported to cause an increase in cyclooxygenase-2 (COX-2) and its downstream product prostaglandin E 2 in normal and transformed oral epithelial cells in 1997 (Kelley et al., 1997) , an interest in the role of COX-2 and its metabolites in tobacco carcinogen-related carcinoma has been increased.
Among the various downstream products of the COX pathway, thromboxane A 2 (TxA 2 ) participates in cancer development and metastasis (Nie et al., 2004; Sakai et al., 2006) . TxA 2 is converted from a COX-2 product, prostaglandin H 2 , by TxA 2 synthase (TxAS). It exhibits diverse biological activities through its signature receptor, TxA 2 receptor. TxA 2 receptor can be activated by binding with its ligand TxA 2 , resulting in a broad range of cellular responses including signaling kinase activation, and the subsequent nuclear events involved in DNA synthesis, cell proliferation and cell survival (Huang et al., 2004) . TxA 2 can act on the TxA 2 -producing cells as a local hormone in autocrine or paracrine systems (Nie et al., 2000; Nakahata, 2008) . TxA 2 is extremely unstable in aqueous solution, being rapidly and non-enzymatically degraded into an inactive form of thromboxane B 2 (TxB 2 ). Therefore, TxAS and TxA 2 receptor have been selected to be the indicators of TxA 2 synthesis and action in ample studies. Overexpression of TxAS has been documented to have a potential role in promoting the progression of many types of cancers (Nie et al., 2004; Sakai et al., 2006; Moussa et al., 2008a; Leung et al., 2009; Cathcart et al., 2010) . In addition to TxAS, the important role of TxA 2 receptor in tumorigenesis and cancer progression has emerged (Sakai et al., 2006; Wei et al., 2007; Li and Tai, 2009; Cathcart et al., 2010) . Particularly, we have previously demonstrated that inhibition of TxAS results in the p27-related induction of cell death or apoptosis in both human non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells (Leung et al., 2009) , and other authors have recently reported that the activation of TxA 2 receptor induces cell proliferation in NSCLC cells (Li and Tai, 2009) .
The role of TxA 2 in tobacco smoke-related lung cancer remains largely unknown, although TxB 2 has been shown to be significantly increased by smoking in lung tumor tissues (McLemore et al., 1988; Fahn et al., 1998; Chen et al., 2006) . Herein, this study was designed to investigate the possible involvement of TxA 2 in NNK-related lung tumor progression.
Results

High expression of TxAS in lung cancer tissues of smokers
Immunohistochemical staining was performed on lung cancer tissues. The scores of the immunohistochemical staining showed that TxAS expression was significantly increased in human lung cancer tumor tissues (B90%, 30 of 37 cases) when compared with the paired corresponding non-tumor tissues (Po0.01; Table 1 ). The finding is in line with a previous study (Ermert et al., 2003) . Strikingly, 100% samples of the smokers (tumor and non-tumor) exhibited positive staining for TxAS (Table 1) . When we used the score 1 (o20%) of TxAS-positive staining as the cutoff value, smokers had higher expression of TxAS in tumor tissues (B93%, 27 of 29 cases) when compared with non-smokers (50%, 4 of 8 cases; Table 1 ). The representative immunohistochemical staining (smokers and non-smokers) is shown in Figure 1a . In conjunction with our previous report showing that lung tumor tissues obtained from patients who smoked showed a higher level of TxB 2 than lung tissues from patients who did not smoke (Chen et al., 2006) , these results suggest that the increased TxAS may contribute to the high level of TxA2 in lung cancer tissues of smokers.
NNK stimulated TxA 2 synthesis in lung cancer cells Based on the above results obtained by immunohistochemical staining, we next sought to detect if NNK can stimulate TxA 2 synthesis in lung cancer cells. Western blot analysis showed that NNK increased TxAS protein level in a time-and dose-dependent manner (Figure 1b ). NNK at 100 nM clearly led to the increase of TxAS protein level and this stimulation reached to a maximum at 10 mM. NNK (10 mM) increased the level of TxAS as early as 1 h after the treatment and the increase continued up to at least 12 h. Using enzyme immunoassay kits, we next measured the effects of NNK on the level of TxB 2 , which is a stable and biologically inactive metabolite of TxA 2 . The result showed that NNK (10 mM) stimulated TxB 2 production by 1.9-fold in NCI-H23 cells (Po0.01) and by 1.6-fold in CRL-2066 cells (Po0.01) when compared with control ( Figure 1c) . Moreover, preincubation with TxAS-specific inhibitor furegrelate significantly attenuated NNK-induced TxB 2 production by nearly 75% (Po0.01) in NCI-H23 cells and 90% (Po0.01) in CRL-2066 cells. In light of the fact that the synthesis of TxA 2 can be directly reflected by the TxAS expression and activity (TxB 2 generation) (Nie et al., 2000 (Nie et al., , 2004 Sakai et al., 2006; Cailleteau et al., 2008) , these results suggest that NNK is able to increase TxA 2 output by stimulating TxAS in lung cancer cells. It should be noted that the elevated TxA 2 level indicates that TxA 2 receptor could be highly activated, which is generally attributed to the fact that TxA 2 is a bioactive agonist that specifically interacts with its receptor on target cells to impart its biologic effects (Nie et al., 2000; Nakahata, 2008) . It was reported that 7 mM of NNK corresponded to the approximate amount found in one pack of cigarettes (Proulx et al., 2005) , and we have observed that the effects of NNK on lung cancer proliferation reach a plateau after its concentration reaches a level of 410 mM (Li et al., 2008 (Li et al., , 2010 . Considering these observations and the data obtained in this study, 10 mM NNK was used for conducting all further experiments.
TxAS inhibitor and TxA 2 receptor antagonist prevented NNK-promoted cell proliferation/survival Inhibition of TxA 2 synthesis by TxAS inhibitors and blockade of TxA 2 action by TxA 2 receptor antagonists appear to be an effective method for evaluation of the role of TxA 2 in tumor progression (Daniel et al., 1999; Nie et al., 2000 Nie et al., , 2004 Nakahata, 2008) . Accordingly, this pharmacological method was adopted in our study. The time course experiments of MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, Figure 2a ). In CRL-2066 cells, it was 126.4 ± 4.8, 141.8 ± 2.7, 144.0 ± 4.8, 159.4 ± 3.3 and 171.0 ± 2.9% of controls, respectively ( Figure 2b ). This finding is consistent with our previous studies (Li et al., 2008 (Li et al., , 2010 . The promoting effect of NNK on the cell proliferation/survival was fully and consistently blocked by the treatment with furegrelate (1 mM) and SQ29548 (5 mM) for 24, 48 or 72 h regardless of lung cancer cell types (Figures 2a and b) . The cell proliferation/survival was below the control level at 24 h after treatment with NNK plus furegrelate or SQ29548 (Figures 2a and b) . The result obtained by MTT assay was confirmed by another two methods for the cell proliferation/survival measurement: bromodeoxyuridine cell proliferation assay, which measures DNA synthesis by enzyme-linked immunosorbent assay (Figure 2c) , and western blot analysis of the proliferating cell nuclear antigen (PCNA) protein (Figure 2d ), which is a typical marker for cell proliferation (Stoimenov and Helleday, 2009 Figure 2e ). U46619 is a stable analog of prostaglandin H 2 and exhibits properties similar to TxA 2 (Coleman et al., 1981) . We utilized MTT assay to investigate the effect of TxA 2 mimetic (TxA 2 receptor agonist) U46619 on the cell proliferation/survival response to NNK when TxAS was inhibited. As shown in Figure 2f , blockade of TxA 2 synthesis by furegrelate for 24 h totally overcame the NNK-induced cell proliferation, whereas the administration of TxA 2 receptor agonist U46619 (1 mM) effectively reconstituted it. In addition, U46619 stimulated a similar proliferative rate of lung cancer cells as NNK. These results provided strong evidence that activation of TxA 2 receptor is necessary for NNKmediated lung cancer cell proliferation/survival.
Blockade of TxA 2 synthesis or action induced the apoptosis of NNK-exposed cells As MTT assay is a quantitative colorimetric assay for mammalian cell proliferation/survival (Mosmann, 1983) , the data obtained by MTT assay implied that NNK may have pro-survival effect to promote tumor cell proliferation. The subsequent experiments were undertaken to examine if the blockage of TxA 2 would affect apoptosis in NNK-exposed cells. TdT-mediated dUTP nick end labeling (TUNEL) method using flow cytometry for apoptosis analysis was performed. As illustrated in Figure 3a , co-treatment with NNK and furegrelate or SQ29548 resulted in a significant increase (4.9-or 3.7-fold) in the fraction of apoptotic cells in NCI-H23 (P ¼ 0.042 and P ¼ 0.031, respectively) when compared with the control. The percentage of TUNEL-positive cells were also significantly higher in CRL-2066 cells treated with furegrelate or SQ29548 in the presence of NNK than the control (5.5-fold, P ¼ 0.009 or 4.6-fold, P ¼ 0.044; Figure 3a ). The trends of apoptosis induced by furegrelate or SQ29548 (in the presence of NNK) in both cell lines were similar. Moreover, protein levels of B-cell lymphoma 2 (Bcl-2), Bax and poly (ADP-ribose) polymerase (PARP) were measured ( Figure 3b ). An increase in antiapoptotic protein Bcl-2 accompanied by the slight decrease in apoptotic protein Bax was observed after 24 h of treatment with NNK. Both furegrelate and SQ29548 reversed the NNK-induced high ratio of Bcl-2/Bax by decreasing Bcl-2 expression and increasing Bax expression. Furthermore, the increase in cleaved PARP accompanied by the decrease in full-length PARP was detected in groups of NNK in combination with furegrelate or SQ29548. Collectively, these results suggested that blockade of TxA 2 synthesis or its receptor prevented NNK-induced cell proliferation through induction of apoptosis. CREB is accountable for the key role of TxA 2 in NNK-mediated cell proliferation/survival CREB, a transcriptional factor, is thought to have a central role in tumor pathogenesis by continually driving the expression of concerned genes through the interaction with a DNA sequence called cyclic adenosine monophosphate response element (CRE: 5 0 -TGACGT CA-3 0 ) (Sakamoto and Frank, 2009 ). To stimulate CRE-dependent transcription, CREB must be activated through phosphorylation at serine 133 (Sakamoto and Frank, 2009 ). In addition, CREB has been identified as a crucial survival factor in lung cancer with convincing evidence, showing the direct key role of phosphorylated CREB in promoting lung cancer cell proliferation (Laag et al., 2006; Aggarwal et al., 2008; Li and Tai, 2009 ). On the basis of these observations, we sought to determine if the involvement of TxA 2 in NNK-induced proliferation is through the activation of CREB. As shown in Figure 4a , even though NNK did not affect CREB expression, it enhanced the phosphorylated CREB. Furegrelate or SQ29548 pre-treatment significantly blocked the NNK-induced increase of phosphorylated CREB. Subsequently, we suppressed the CREB activity in both cell lines by knockdown of CREB expression with small interference RNA (siRNA). Western blot analysis indicated that the expression and phosphorylation of CREB were significantly suppressed by transfection of CREB siRNA in both cell lines (Figure 4b ). It is well known that both PCNA and Bcl-2 are CREcontaining genes (Ciani et al., 2002; Sakamoto and Frank, 2009) . Western blot analysis also demonstrated that CREB siRNA notably attenuated the augmented PCNA and Bcl-2 expression induced by NNK (Figure 4c) , the result of which is similar to that noted with furegrelate or SQ29548 pretreatment (Figures 2d  and 3b) . The results observed in U46619-exposed cells were similar to the effects seen in the cells exposed to NNK. Furthermore, MTT assay showed that the similar proliferative/survival rates of lung cancer cells by NNK and U46619 were substantially blocked by CREB siRNA (Figure 4d ). These results suggest that CREB may function as a key effector of TxA 2 in NNK-exposed cells.
PI3K/Akt and ERK rather than JNK and p38 pathways were mediated by TxA 2 in the NNK-exposed cells In order to further gain some insight into the signaling mechanism whereby TxA 2 is involved in NNK-induced cell proliferation/survival, we employed western blot analysis to analyze Akt and extracellular signal-regulated kinase (ERK) in the cell survival pathway. We used the phosphatidylinositol 3-kinase (PI3K)-specific inhibitor wortmannin to block Akt pathway, as the specific inhibitors of Akt are not available yet and Akt is a pivotal downstream component of PI3K pathway (Sebolt-Leopold and Herrera, 2004) . As indicated in Figure 5 , either furegrelate or SQ29548 partially but markedly reduced the phosphorylation of Akt induced by NNK whereas wortmannin abrogated it. We observed similar changes in phosphorylated ERK ( Figure 5 ). In these cells, additional control experiments were performed with TxA 2 mimetic U46619, which yielded an almost identical stimulation of phosphorylated Akt and phosphorylated ERK as NNK.
It is well known that mitogen-activated protein kinase (MAPK) signaling pathways, which mainly include ERK, p38 and c-Jun NH(2)-terminal kinase (JNK) three members, are crucial for cell proliferation/survival in cancer Wei et al., 2007) . Therefore, we also examined whether TxA 2 affected their activation in the cells treated with NNK. As shown in Figure 5 , phosphorylated JNK was mildly increased by NNK, but it was not obviously affected by furegrelate, SQ29548 and U46619. In contrast, phosphorylated p38 expression could be slightly reduced by furegrelate and SQ29548 and only increased by U46619 ( Figure 5 ). The results obtained in both cell lines were similar, and the expression of total Akt, ERK, JNK or p38 protein was not changed by the above treatments.
CREB is located downstream of the PI3K/Akt and ERK pathways in NNK-treated cells The final series of experiments employed kinase inhibitors to investigate the action of PI3K/Akt and ERK pathways on CREB phosphorylation in NNK-exposed cells. As shown in Figure 6 , CAY10561 effectively attenuated NNK-induced CREB activation (phosphorylated CREB) in both cell lines, whereas wortmannin moderately prevented it. The attenuation of CREB activation by wortmannin was greater in CRL-2066 cells than in NCI-H23 cells. The results observed in U46619-exposed cells were similar to the effects seen in the cells exposed to NNK. No alteration was detectable regarding the expression of total CREB in both cell lines tested.
Discussion
There are an increasing number of publications describing the potential role of TxA 2 and its related molecules in promoting progression of lung cancer (Ermert et al., 2003; Wei et al., 2007; Leung et al., 2009; Li and Tai, 2009) . Unfortunately, the possible role of TxA 2 in smoking-associated lung cancer has received limited attention. In this study, we have demonstrated that NNK could stimulate the synthesis and action of TxA 2 in lung cancer cells. Such a response was directly correlated with the activation of PI3K/Akt and ERK pathways, leading to the activation of CREB.
We have shown that the synthesis of TxA 2 , reflected by TxAS expression and its activity (TxB 2 formation), is elevated in lung cancer tissues of smokers and in lung cancer cells exposed to tobacco smoking carcinogen NNK. This finding is supported by other reports (McLemore et al., 1988; Fahn et al., 1998) . NNK is the principal tobacco smoke carcinogen, and it can increase the expression and activity of COX-2, an upstream enzyme of TxA 2 , in lung cancer (El-Bayoumy et al., 1999; Grozio et al., 2007) . The synthesis of TxA 2 by TxAS is dependent on COX activities as COX-1 and COX-2 provide TxAS with the substrate, prostaglandin H 2 (Nie et al., 2004) . In addition, it has been recently demonstrated that nicotine plus its five major metabolites were significantly elevated in smokers when compared with non-smokers, with a significant high level of TxB 2 (Calapai et al., 2009) . Thus, it is reasonable to postulate that NNK stimulates TxA 2 synthesis in lung cancer cells. This hypothesis was verified by the data that NNK increased TxAS expression and TxB 2 generation in lung cancer cells. Blockade of TxA 2 synthesis by TxAS-specific inhibitor furegrelate not only completely prevented NNK-induced high TxB 2 level but also significantly inhibited NNK-promoted cell proliferation/survival, and TxA 2 mimetic (TxA 2 receptor Figure 4 The involvement of CREB in NNK-mediated regulation of TxA 2 and cell proliferation/survival. (a) The effect of furegrelate or SQ2948 on NNK-induced CREB phosphorylation. The cells were serum starved for 24 h and then treated with NNK (10 mM) alone for 30 min. The cells were incubated with furegrelate (1 mM) or SQ29548 (5 mM) for 20 min before stimulation with NNK (10 mM) for 30 min. The cells without treatment served as controls, and the cells exposed to furegrelate (1 mM) or SQ29548 (5 mM) alone for entire duration of treatment were set up as additional controls. The phosphorylated CREB (pCREB, 43 kDa) and total CREB (43 kDa) levels were determined by western blot analysis. The figure is a representative result selected from three independent experiments. (b) CREB expression and phosphorylation were suppressed by CREB siRNA. Cells were transiently transfected with either non-target siRNA (control siRNA) or CREB siRNA for 24 h. Total protein was extracted and subjected to western blot analysis for detection of pCREB and CREB level. Actin was used as an equal loading control. The figure is the representative result selected from three independent experiments. (c, d) Cells were transiently transfected with either non-target siRNA or CREB siRNA for 24 h, in the absence or presence of NNK (10 mM) or U46619 (1 mM). The cells transfected with non-target siRNA without chemical treatment were set up as the control for all other groups. (c) The expression of PCNA (36 kDa) and Bcl-2 (28 kDa) was measured by western blot analysis. Actin was used as an equal loading control. The figure is the representative result selected from three independent experiments. (d) Cell proliferation/ survival was assessed by MTT assay, and the results were presented as percentage of controls. Data are expressed as mean ± s.d. of three independent experiments done in quadruplicate. *Po0.05, **Po0.01. ctr, control; Fu, furegrelate; N, NNK; NT siRNA, non-target siRNA; SQ, SQ29548; U, U46619. agonist) U46619 induced a similar proliferative/survival rate as NNK. These results suggest that TxA 2 has a functional role in mediating NNK-induced lung cancer cell proliferation/survival. Moreover, when TxAS was inhibited, U46619 could reconstitute a near-full proliferative/survival response to NNK, indicating that TxA 2 receptor is necessary for the action of TxA 2 in NNKexposed lung cancer cells. Furthermore, TxA 2 receptor antagonist SQ29548 that blocks TxA 2 binding to its receptor as well as TxAS-specific inhibitor furegrelate significantly inhibited the pro-proliferative/survival effect of NNK and blocked NNK-induced PCNA and Bcl-2 elevation. These findings support that both activation of TxA 2 receptor and synthesis of TxA 2 have a critical role in NNK-promoted cell proliferation/ survival. Our findings can be substantiated by several lines of evidence. For example, it has recently been demonstrated that the activation of TxA 2 receptor by I-BOP (another TxA 2 mimetic) promoted cell proliferation in lung A549 (NSCLC) cells (Li and Tai, 2009 ). In addition, the bladder cancer cells transfected with b-isoform of TxA 2 receptor and stimulated with U46619 resulted in a significant increase in cellular growth rate and PCNA expression (Moussa et al., 2008b) . A recent study has also reported that treatment of two NSCLC cell lines with another selective TxAS inhibitor ozagrel induced a significant reduction in cell proliferation (Cathcart et al., 2010) . We have further demonstrated that the inhibitory effect of furegrelate or SQ29548 on NNK-promoted cell proliferation/survival is in part due Figure 5 Effects of blocking TxA 2 synthesis and action on Akt, ERK, JNK and p38 in cells exposed to NNK. The cells were serum starved for 24 h and then treated with NNK (10 mM) alone or NNK (10 mM) plus U46619 (1 mM) for 30 min. The cells were treated with furegrelate (1 mM), SQ29548 (5 mM) or various kinase inhibitors for 20 min before stimulation with NNK for another 30 min. The cells without treatment served as controls, and the cells treated with furegrelate (1 mM), SQ29548 (5 mM) or each of the inhibitors alone for entire duration of treatment were set up as additional controls. The cells exposed to U46619 (1 mM) alone for 30 min were also set up as additional controls. The levels of phosphorylated Akt (pAkt, 60 kDa), total Akt (60 kDa), phosphorylated ERK (pERK, 42/44 kDa), total ERK (42/44 kDa), phosphorylated JNK (pJNK, 46/54 kDa), total JNK (46/54 kDa), phosphorylated p38 (pp38, 40 kDa) or total p38 (40 kDa) were detected by western blot analysis. The figure is the representative result selected from three independent experiments. Fu, furegrelate; N, NNK; SQ, SQ29548, U, U46619. KI is each of the kinase inhibitors (ERK, 5 mM CAY10561; JNK, 30 mM SP600125; p38, 10 mM SB203580; PI3K/Akt, 200 nM wortmannin). Figure 6 The action of PI3K/Akt or ERK pathways on CREB activation in NNK-exposed cells. The cells were serum starved for 24 h and then treated with NNK (10 mM) alone for 30 min. The cells were incubated with wortmannin (200 nM) or CAY10561 (5 mM) for 20 min before stimulation with NNK (10 mM) or U46619 (1 mM) for 30 min. The cells without treatment served as controls, and the cells exposed to each of the inhibitors alone for entire duration of treatment were set up as additional controls. The phosphorylated CREB (pCREB, 43 kDa) and total CREB (43 kDa) levels were determined by western blot analysis. The figure is a representative result selected from three independent experiments. CAY, CAY10561; N, NNK; U, U46619; Wort, wortmannin.
to an increase in apoptosis regardless of cell type, which is supported by the previous reports showing that inhibition of TxAS resulted in apoptosis in bladder (Moussa et al., 2008a) and lung (Cathcart et al., 2010) cancer cells, and that treatment with TxA 2 receptor antagonists also caused significant apoptosis in bladder cancer cells (Moussa et al., 2008b) .
By modulating gene expression that are critically important in the tumor pathogenesis, transcription factors are believed to be the final regulators of the central processes of tumor progression such as proliferation and survival (Sakamoto and Frank, 2009) . CREB is one such transcription factor (Sakamoto and Frank, 2009) , and it is constitutively activated in both NSCLC and SCLC cells (Ma et al., 2007; Aggarwal et al., 2008) . Additionally, CREB has been shown to be activated by NNK, TxA 2 or TxA 2 mimetic in lung cancer cells (Laag et al., 2006; Wei et al., 2007; Li and Tai, 2009 ). Therefore, CREB activation and its related proteins, PCNA and Bcl-2, were evaluated in this study. We demonstrated that either furegrelate or SQ29548 dramatically blocked NNK-induced CREB activation, which is consistent with the finding that either furegrelate or SQ29548 significantly inhibited the NNKpromoted cell proliferation/survival. Moreover, CREB siRNA prevented the NNK or U46619-induced PCNA and Bcl-2 elevation and abolished the enhanced cell proliferation/survival induced by NNK or U46619 in both types of lung cancer cells tested. In support of these results, it has been reported that the upregulation of PCNA and Bcl-2 could occur through the increase in their transcription factor CREB phosphorylation (Ciani et al., 2002) , and that inhibition of CREB activity effectively suppressed the proliferation and survival of NSCLC cells (Aggarwal et al., 2008) . These data are in line with our results showing that TxA 2 is involved in NNK-promoted cell proliferation/survival by activating CREB. The conclusion supports the fact that CREB is an effector for a variety of receptors, including receptors for growth factors, hormones and prostaglandins (Aggarwal et al., 2008) .
We have further examined the signaling mechanism whereby TxA 2 is involved in NNK-promoted cell proliferation/survival. The PI3K/Akt and MAPK pathways are known to be the crucial pro-survival signaling and have critically important roles in cellular proliferation and growth (Merighi et al., 2006) . It is noted that the PI3K/Akt and ERK pathways are two principal signalings associated with NNK (West et al., 2003; Hung and Hung, 2009 ). These two pathways can also be activated by TxA 2 mimetic in cancer cells Wei et al., 2007) . Although there are common signaling targets, no study has been previously done to correlate NNK with TxA 2 . In this study, we demonstrated that short-term NNK exposure led to high levels of phosphorylated Akt or ERK in lung cancer cells, which is in good agreement with a recent study (Nishioka et al., 2010) . We further showed that TxA 2 mimetic U46619 could yield similar stimulation of phosphorylated Akt or ERK as NNK, confirming the role of TxA 2 in the upregulation of phosphorylated Akt or ERK. Importantly, either furegrelate or SQ29548 could inhibit the NNK-mediated activation of Akt and ERK, indicating that the effect of NNK depends on TxAS and TxA 2 receptor. However, we could not find a strict correlation between NNK and TxA 2 in the activation of both p38 MAPK and JNK pathways. As a matter of fact, the phosphorylation of these two kinases in response to TxA 2 may be somewhat controversial. A linkage between the level of phosphorylated JNK and the sensitivity to TxA 2 has been previously reported in cells of other tumor types (Miggin and Kinsella, 2001; Li et al., 2007) , whereas studies in lung cancer cells have found no correlation . The data on the response of p38 phosphorylation to NNK in cancer studies are limited, whereas it has been well established that NNK can stimulate JNK activation in lung cancer of animal models (Kim et al., 2006; Lu et al., 2006) . In this study, the phosphorylated p38 was shown to be influenced only by TxA 2 , whereas activation of JNK was demonstrated to be stimulated merely by NNK. The result indicated that the contribution of TxA 2 to NNKpromoted cell proliferation/survival is likely because of the activation of ERK rather than p38 and JNK in MAPK family, and that NNK may have some effects that are independent of TxA 2 . We were unable to correlate the role of TxA 2 with JNK phosphorylation, suggesting that the effect of NNK is independent of JNK activation.
CREB is known to be activated through phosphorylation by several kinases, including PI3K/Akt and ERK (Sakamoto and Frank, 2009) . ERK has been well established to be a key upstream of CREB in NSCLC cells Aggarwal et al., 2008; Li and Tai, 2009) , whereas there is little information on the action of PI3K/Akt on CREB activity in lung cancer cells. Our study has confirmed that ERK is significantly involved in CREB phosphorylation in lung cancer cells. However, the activation of PI3K/Akt by NNK contributed to CREB phosphorylation to a lesser degree, as the PI3K/Akt pathway inhibitor wortmannin blocks either NNK-or U46619-induced CREB activation moderately. Moreover, the inhibition of CREB activation by wortmannin was greater in CRL-2066 (SCLC) cells than in NCI-H23 (NSCLC) cells stimulated with either NNK or U46619. Such diverse outcomes suggest that CREB activation may be one, but not the only, mechanism responsible for the involvement of TxA 2 in NNKinduced lung cancer cell proliferation.
It is well known that besides NNK, cigarette smoking can also generate other chemical carcinogens such as NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), NNN (N-nirosonornicotine) and NAB (N 0 -nitrosoanabasine) (Hoffmann et al., 1994) . Based on the experiment of lung tumorigenesis in animal models, the ranking of potency of these carcinogens are as follows: NNK4NNAL4NNN4NAB (Amin et al., 1996) . This study is thus focused on the most potent cigarettesmoking carcinogen, NNK. Whether other tobacco smoking-generated lung carcinogens can act in similar or same way as NNK to influence the TxA 2 requires further investigation.
In summary, this study has delineated the involvement of TxA 2 in NNK-promoted lung cancer cell proliferation/survival and its signaling mechanism (Figure 7) , which advances our current knowledge of how NNK contributes to tumor growth of lung cancer. NNK may activate TxA 2 receptor via stimulation of TxA 2 synthesis. TxA 2 activates the transcription factor CREB whose target genes include PCNA and Bcl-2, thereby contributing to NNK-induced lung cancer cell proliferation/survival. The PI3K/Akt and ERK pathways are involved in NNK-mediated tumor growth. ERK pathway is essential for the NNK-induced activation of CREB. To a lesser degree, PI3K/Akt pathway may also have a positive role. Thus, our study has highlighted the significance of TxA 2 -related pathway with respect to smoking-associated lung cancer progression. The findings may help to develop drugs affecting TxA 2 synthesis or action to treat this deadly disease.
Materials and methods
Human lung tissue and immunohistochemical analysis
A total of 37 pairs of tumor and non-tumor lung tissues were obtained from lung cancer patients who underwent surgical resection at the Prince of Wales Hospital. Tumor tissue samples were taken from the central part of the tumors. Of the 37 patients, 29 were cigarette smokers with an average smoking history of 428 years and the other 8 patients were nonsmokers. The samples included 11 pairs of squamous cell carcinoma tissues, 11 pairs of adenocarcinoma tissues, 5 pairs of large cell carcinoma tissues and 10 pairs of poorly differentiated carcinoma tissues. All types of tissue specimens were confirmed by histological examination. The tissue samples were stored in a liquid nitrogen tank until the experiments were performed. The tissues were sectioned and immunohistochemical staining was carried out using rabbit anti-TxAS antibody (Cayman Chemical, Ann Arbor, MI, USA).
Cell lines and cell culture
Two cell lines were selected in this study. NCI-H23 and CRL-2066 were obtained from American Type Culture Collection (Rockville, MD, USA). The former is a NSCLC cell line whereas the latter is a SCLC cell line. These two cell lines were grown in Dulbecco's modified Eagle's medium and Waymouth's MB 752/1 medium (Gibco, Grand Island, NY, USA), respectively.
Chemicals and drug treatment
Furegrelate (TxAS-specific inhibitor), SQ29548 (TxA 2 receptor antagonist, also known as TxA 2 functional antagonist; Nie et al., 2004) , U46619 (TxA 2 receptor agonist, also known as TxA 2 mimetic; Li et al., 2007) , CAY10561 (ERK-specific inhibitor; Aronov et al., 2007) and SP600125 (the JNK inhibitor) were purchased from Cayman Chemical. NNK and SB203580 (p38 MAPK-specific inhibitor) were obtained from Toronto Research Chemicals Inc. (Toronto, North York, Canada). The PI3K-specific inhibitor, wortmannin, was purchased from Sigma Chemical Co. (St Louis, MO, USA). The concentrations of all chemicals used were based on the product datasheets and previous publications (Daniel et al., 1999; de Leval et al., 2006; Aronov et al., 2007; Li et al., 2007; Wei et al., 2007; Cailleteau et al., 2008; Moussa et al., 2008a, b) , and they were proven to be optimal in the present study. Dimethylsulfoxide, an organic solvent, was used in the treatment with different drugs. In all experiments, the final concentration of dimethylsulfoxide did not exceed 0.005%, which did not induce differentiation or cell death in our model studied.
TxB 2 enzyme immunoassay assay TxB 2 was detected by peroxidase-labeled TxB 2 conjugates using an enzyme immunoassay kit according to a previous description (Chen et al., 2006) .
MTT assay
Tumor cell proliferation and survival was determined by MTT assay, which was performed as previously described (Chen et al., 2006; Li et al., 2008 Li et al., , 2010 .
Bromodeoxyuridine cell proliferation assay Proliferation/survival of lung cancer cells was further studied using a bromodeoxyuridine labeling enzyme-linked immunosorbent assay kit (Roche Applied Science, Penzberg, Germany), which was performed as previously described (Chen et al., 2006; Li et al., 2008 Li et al., , 2010 . TUNEL Apoptotic cells were measured by an APO-BRDU TUNEL kit (Phoenix Flow Systems, San Diego, CA, USA), which was performed as previously described (Chen et al., 2006; Li et al., 2008 Li et al., , 2010 .
Transfection of cells with CREB siRNA Lung cancer cells were seeded at the same density into a sixwell culture plate, and then incubated overnight to allow cells to attach to the plate. CREB siRNA and non-target siRNA (control siRNA) were transfected into the cells with the aid of Lipofectamine 2000 reagents (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instruction (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After 5-h transfection, the cells were recovered with the fresh culture medium. After 24-h recovery, the cells were exposed to the low-serum media (2% fetal bovine serum) with or without NNK or U46619 for MTT assay or other experiments.
Western blot analysis
Western blot was performed as previously described (Li et al., 2008 (Li et al., , 2010 . The following antibodies were used for western blotting: mouse monoclonal antibody against total p38 MAPK (1:200), rabbit polyclonal antibodies against TxAS (1:200), TxA 2 receptor (1:200), phosphorylated p38 MAPK (1:1000) and phosphorylated ERK (1:1000) (Cayman Chemical), mouse monoclonal antibody against PCNA (1:5000), goat polyclonal antibody against b-actin (1:1000). The following antibodies were used for the western blotting. Mouse monoclonal antibody against total p38 MAPK (1:200), rabbit polyclonal antibodies against TxAS (1:200), TxA 2 receptor (1:200), phosphorylated p38 MAPK (1:1000) and phosphorylated ERK (1:1000) were all purchased from Cayman chemical. Mouse monoclonal antibody against PCNA (1:5000), goat polyclonal antibody against b-actin (1:1000), rabbit polyclonal antibodies against phosphorylated Akt (Thr308) (1:1000), total Akt (1:1000), PARP (1:1000), Bax (1:1000) and Bcl-2 (1:1000)
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit monoclonal antibody against phosphorylated CREB (ser133) and total-CREB (1:1000), mouse monoclonal antibodies against total ERK (1:1000), phosphorylated JNK (1:1000) and total JNK (1:1000) were from Cell Signaling Technology (Beverly, MA, USA). Representative results reported were from three independent experiments. Statistical analysis SPSS 16.0 for windows software was used for statistical data analysis (SPSS, Chicago, IL, USA). The Wilcoxon signedranks test was used when appropriate to compare the difference in TxAS expression between tumor and non-tumor lung tissues. The Fisher's exact test was used to compare the difference in TxAS expression in tumor tissues between smokers and non-smokers. One-way ANOVA followed by Dunnett's test was used for comparing multiple groups against a single control, whereas Student's t-test was employed for comparison between two groups. The acceptable level of significance was Po0.05 or 0.01. All data are shown as mean ± s.d. of at least three independent experiments.
